Australia markets open in 3 hours 1 minute

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
1.6800+0.0200 (+1.20%)
At close: 04:00PM EDT

InflaRx N.V.

Winzerlaer Str. 2
Jena 07745
49 3641 508 180

Full-time employees62

Key executives

NameTitlePayExercisedYear born
Dr. Niels C. Riedemann M.D., Ph.D.Co-Founder, CEO & Executive DirectorN/AN/A1973
Prof. Renfeng Guo M.D.Co-Founder, Chief Scientific Officer & Executive DirectorN/AN/A1970
Dr. Thomas Taapken Ph.D.Chief Financial OfficerN/AN/A1965
Ms. Derval O'CarrollSenior VP and Global Head of Regulatory Affairs & ComplianceN/AN/A1966
Dr. Camilla Chong M.D.Chief Medical OfficerN/AN/A1966
Mr. Jan Medina CFAHead of Investor Relations & VPN/AN/AN/A
Mr. Christian SchmidVP and Head of Legal Affairs & General CounselN/AN/AN/A
Ms. Nicole BertschSenior Director & Head of Human ResourcesN/AN/AN/A
Dr. Maria Habel PH.D.VP, Head of Preclinical R&D and QCN/AN/A1982
Dr. Bruce P. Burnett Ph.D.VP & Head of Medical AffairsN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Corporate governance

InflaRx N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.